Aura Biosciences, Inc. (NASDAQ:AURA) Shares Bought by Long Focus Capital Management LLC

Long Focus Capital Management LLC grew its position in Aura Biosciences, Inc. (NASDAQ:AURA) by 123.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,537,774 shares of the company’s stock after buying an additional 1,404,228 shares during the quarter. Aura Biosciences accounts for 0.7% of Long Focus Capital Management LLC’s holdings, making the stock its 25th largest holding. Long Focus Capital Management LLC owned approximately 5.08% of Aura Biosciences worth $20,861,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Vanguard Group Inc. boosted its holdings in Aura Biosciences by 6.2% during the 4th quarter. Vanguard Group Inc. now owns 1,917,730 shares of the company’s stock valued at $15,764,000 after acquiring an additional 112,296 shares during the period. Franklin Resources Inc. boosted its stake in shares of Aura Biosciences by 3.2% in the fourth quarter. Franklin Resources Inc. now owns 1,723,063 shares of the company’s stock valued at $14,164,000 after purchasing an additional 54,103 shares during the period. Levin Capital Strategies L.P. grew its holdings in shares of Aura Biosciences by 169.1% in the fourth quarter. Levin Capital Strategies L.P. now owns 1,247,619 shares of the company’s stock valued at $10,255,000 after purchasing an additional 783,984 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Aura Biosciences by 0.4% in the fourth quarter. Geode Capital Management LLC now owns 1,012,799 shares of the company’s stock valued at $8,327,000 after purchasing an additional 3,972 shares in the last quarter. Finally, State Street Corp increased its stake in Aura Biosciences by 3.7% during the 3rd quarter. State Street Corp now owns 754,803 shares of the company’s stock worth $6,725,000 after buying an additional 26,841 shares during the period. Hedge funds and other institutional investors own 96.75% of the company’s stock.

Aura Biosciences Trading Up 2.5 %

Shares of AURA stock opened at $5.71 on Wednesday. The company has a market cap of $286.78 million, a P/E ratio of -3.30 and a beta of 0.43. The firm has a fifty day moving average price of $6.62 and a 200 day moving average price of $8.12. Aura Biosciences, Inc. has a 12 month low of $4.30 and a 12 month high of $12.38.

Aura Biosciences (NASDAQ:AURA) last released its quarterly earnings data on Monday, March 24th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.09). On average, equities analysts forecast that Aura Biosciences, Inc. will post -1.66 EPS for the current year.

Insider Transactions at Aura Biosciences

In related news, insider Conor Kilroy sold 7,162 shares of Aura Biosciences stock in a transaction on Wednesday, April 16th. The shares were sold at an average price of $5.49, for a total transaction of $39,319.38. Following the sale, the insider now directly owns 179,313 shares in the company, valued at $984,428.37. This trade represents a 3.84 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In the last quarter, insiders sold 14,148 shares of company stock worth $91,434. 5.40% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several equities analysts have commented on the stock. JMP Securities set a $19.00 price target on shares of Aura Biosciences in a research report on Wednesday, March 26th. Lifesci Capital upgraded Aura Biosciences to a “strong-buy” rating in a report on Friday, January 31st. Citigroup reissued an “outperform” rating on shares of Aura Biosciences in a research note on Wednesday, March 26th. Finally, HC Wainwright set a $25.00 price target on Aura Biosciences in a research report on Tuesday, March 25th. Six research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, Aura Biosciences presently has a consensus rating of “Buy” and an average price target of $22.75.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.